On December 20, 2016, Zimmer Biomet sent an Urgent Medical Device Recall Notice to health care providers who used the Comprehensive Reverse Shoulder Device.
Patients who received total shoulder replacements using the device were also notified.
The U.S. Food and Drug Administration (FDA) has identified the notice as a Class I recall.
This is the most serious type of recall issued by the agency.
The use of the affected devices may cause serious injuries or death.
A conventional shoulder replacement device mimics the normal anatomy of the shoulder.
A plastic cup is fitted into the shoulder socket and a metal ball is attached to the top of the upper arm bone.
A reverse should device, otherwise called a reverse total shoulder replacement (RTSA), the socket and metal ball are switched.
The metal ball is fixed to the socket and the plastic cup is fixed to the upper end of the humerus.
A reverse total shoulder replacement is more effective for patients with cuff tear arthropathy because it relies on different muscles to move the arm.
In a patient with a large rotator cuff tear and cuff tear arthropathy, a reverse total shoulder replacement relies on the deltoid muscle, instead of the rotator cuff, to power and position the arm.
Complication rates after reverse total shoulder arthroplasty are three to five times that of conventional total shoulder replacement arthroplasty.
This is according to a study published in the journal Current Reviews in Musculoskeletal Medicine.
The complications described in the study included:
Despite the benefits of the RTSA, patients who undergo this procedure are often subject to complications similar to conventional total shoulder arthroplasty as well as unique to RTSA because of the major anatomical, physiological, and bio-mechanical changes made to the shoulder joint.
Patients wondering if the Reverse Shoulder Device recall applies to them, may find this article helpful.
Experienced Attorney & Legal SaaS CEO
With over 25 years of legal experience, Jessie is an Illinois lawyer, a CPA, and a mother of three. She spent the first decade of her career working as an international tax attorney at Deloitte.
In 2009, Jessie co-founded her own law firm with her husband – which has scaled to over 30 employees since its conception.
In 2016, Jessie founded TruLaw, which allows her to collaborate with attorneys and legal experts across the United States on a daily basis. This hypervaluable network of experts is what enables her to share reliable legal information with her readers!
Here, at TruLaw, we’re committed to helping victims get the justice they deserve.
Alongside our partner law firms, we have successfully collected over $3 Billion in verdicts and settlements on behalf of injured individuals.
Would you like our help?
At TruLaw, we fiercely combat corporations that endanger individuals’ well-being. If you’ve suffered injuries and believe these well-funded entities should be held accountable, we’re here for you.
With TruLaw, you gain access to successful and seasoned lawyers who maximize your chances of success. Our lawyers invest in you—they do not receive a dime until your lawsuit reaches a successful resolution!
Do you believe you’re entitled to compensation?
Use our Instant Case Evaluator to find out in as little as 60 seconds!
Camp Lejeune’s water contamination issue spanned several decades starting in the 1950s. Exposure to these chemicals has been linked to various serious health issues, including cancer, organ diseases, and death.
Research is increasingly suggesting a link between the use of Tylenol during pregnancy and the development of neurodevelopmental disorders, such as autism and ADHD, in infants.
Legal action is being taken against manufacturers of Aqueous Film-Forming Foam (AFFF), a chemical used in fighting fires. The plaintiffs allege that exposure to the foam caused health issues such as cancer, organ damage, and birth and fertility issues.
Here, at TruLaw, we’re committed to helping victims get the justice they deserve.
Alongside our partner law firms, we have successfully collected over $3 Billion in verdicts and settlements on behalf of injured individuals.
Would you like our help?
Weis Market Inc., a Mid-Atlantic food retailer based in Sunbury, Pennsylvania, has recalled its 48-ounce containers of Weis Quality Brownie Moose Tracks Ice Cream because the product may contain traces of egg, an allergen not declared on the ingredient statement label, according to the FDA.
Marlex Pharmaceuticals, Inc., of New Castle, Delaware, has announced a voluntary, consumer-level recall of one lot of Digoxin Tablets USP, 0125mg, as well as one lot of Digoxin Tablets USP, 0.25mg, because the labels of both products have been mixed up, according to the FDA.